The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10828 malaria professionals are enjoying the free benefits of MalariaWorld today

hemolytic anemia

Brief Report: Hydroxychloroquine does not induce hemolytic anemia or organ damage in a "humanized" G6PD A- mouse model

October 6, 2020 - 12:34 -- Open Access
Author(s): 
Zuchelkowski BE, Wang L, Gingras S, Xu Q, Yang M, Triulzi D, Page GP, Gordeuk VR, Kim-Shapiro DB, Lee JS, Gladwin MT
Reference: 
PLoS One. 2020 Oct 2;15(10):e0240266

Hydroxychloroquine (HCQ) is widely used in the treatment of malaria, rheumatologic disease such as lupus, and most recently, COVID-19. These uses raise concerns about its safe use in the setting of glucose-6-phosphate dehydrogenase (G6PD) deficiency, especially as 11% of African American men carry the G6PD A- variant. However, limited data exist regarding the safety of HCQ in this population.

Delayed-Onset Hemolytic Anemia in Patients with Travel-Associated Severe Malaria Treated with Artesunate, France, 2011–2013

April 3, 2015 - 15:46 -- Open Access
Author(s): 
Stéphane Jauréguiberry, Marc Thellier, Eric Caumes, et al.
Reference: 
Emmerging Infectious Diseases Volume 21, Number 5—May 2015

We prospectively evaluated a cohort of 123 patients in France who had severe imported malaria that was treated with artesunate; our evaluation focused on outcome, adverse events, and postartesunate delayed-onset hemolysis (PADH). Of the 123 patients, 6 (5%) died. Overall, 97 adverse events occurred.

Subscribe to RSS - hemolytic anemia